The APIs listed below are the main Synthetic Peptide ingredients that are presently available from LGM Pharma:
- Bivalirudin
- Cetrorelix Acetate
- Deslorelin Acetate
- Desmopressin Acetate
- Enfuvirtide
- Eptifibatide
- Exenatide
- Ganirelix Acetate
- Gonadorelin Acetate
- Goserelin Acetate
- Histrelin Acetate
- Icatibant Acetate
- Lanreotide Acetate
- Leuprolide Acetate
- Linaclotide
- Liraglutide
- Octreotide Acetate
- Oxytocin
- Pramlintide Acetate
- Teriparatide Acetate
- Terlipressin Acetate
- Tetracosactide
- Triptorelin Acetate
We constantly aim to provide top technical support and full regulatory documentation (TDP / CTD / E-DMF / CEP / US-DMF etc…) even for the most recently approved APIs, originating from EU-GMP certified and US-FDA approved production facilities. Many of the above APIs are manufactured via non-infringing routes of synthesis and would be suitable for Paragraph IV challenges / early launch in regulated markets.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.
